Market Research Logo

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015

Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015

Summary

Global Markets Direct’s, ‘Nasopharyngitis (Common Cold) - Pipeline Review, H2 2015’, provides an overview of the Nasopharyngitis (Common Cold)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Nasopharyngitis (Common Cold), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Nasopharyngitis (Common Cold) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Nasopharyngitis (Common Cold)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Nasopharyngitis (Common Cold) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Nasopharyngitis (Common Cold) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Nasopharyngitis (Common Cold) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Nasopharyngitis (Common Cold)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Nasopharyngitis (Common Cold) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline


Introduction
Global Markets Direct Report Coverage
Nasopharyngitis (Common Cold) Overview
Therapeutics Development
Pipeline Products for Nasopharyngitis (Common Cold) - Overview
Pipeline Products for Nasopharyngitis (Common Cold) - Comparative Analysis
Nasopharyngitis (Common Cold) - Therapeutics under Development by Companies
Nasopharyngitis (Common Cold) - Therapeutics under Investigation by Universities/Institutes
Nasopharyngitis (Common Cold) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Unknown Stage Products
Nasopharyngitis (Common Cold) - Products under Development by Companies
Nasopharyngitis (Common Cold) - Products under Investigation by Universities/Institutes
Nasopharyngitis (Common Cold) - Companies Involved in Therapeutics Development
Charleston Laboratories, Inc.
Cocrystal Pharma, Inc.
Neos Therapeutics, Inc.
Orbis Biosciences, Inc.
Vernalis Plc
Nasopharyngitis (Common Cold) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
(chlorpheniramine maleate + codeine) - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Antibody to Target TRIM-21 for Gastrointestinal and Ear Nose Throat Disorders - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCP-05 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCP-06 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCP-07 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CCP-08 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CLAT-313 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
guaifenesin ER - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule for Cough and Cold - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecule to Inhibit MAPK13 for Asthma and Cold - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit RNA Dependent RNA Polymerase for Common Cold - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Nasopharyngitis (Common Cold) - Recent Pipeline Updates
Nasopharyngitis (Common Cold) - Dormant Projects
Nasopharyngitis (Common Cold) - Discontinued Products
Nasopharyngitis (Common Cold) - Product Development Milestones
Featured News & Press Releases
Jun 11, 2015: Vernalis announces CCP-07 starts 12 month stability testing
Jul 22, 2014: Third Product in Vernalis' Cough Cold Pipeline (CCP-08) Achieves Proof-of-Concept
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2015
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Comparative Analysis by Unknown Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Nasopharyngitis (Common Cold) - Pipeline by Charleston Laboratories, Inc., H2 2015
Nasopharyngitis (Common Cold) - Pipeline by Cocrystal Pharma, Inc., H2 2015
Nasopharyngitis (Common Cold) - Pipeline by Neos Therapeutics, Inc., H2 2015
Nasopharyngitis (Common Cold) - Pipeline by Orbis Biosciences, Inc., H2 2015
Nasopharyngitis (Common Cold) - Pipeline by Vernalis Plc, H2 2015
Assessment by Monotherapy Products, H2 2015
Assessment by Combination Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Nasopharyngitis (Common Cold) Therapeutics - Recent Pipeline Updates, H2 2015
Nasopharyngitis (Common Cold) - Dormant Projects, H2 2015
Nasopharyngitis (Common Cold) - Discontinued Products, H2 2015
List of Figures
Number of Products under Development for Nasopharyngitis (Common Cold), H2 2015 8
Number of Products under Development for Nasopharyngitis (Common Cold) - Comparative Analysis, H2 2015 9
Number of Products under Development by Companies, H2 2015 10
Comparative Analysis by Early Stage Products, H2 2015 13
Assessment by Monotherapy Products, H2 2015 22
Number of Products by Top 10 Targets, H2 2015 24
Number of Products by Stage and Top 10 Targets, H2 2015 24
Number of Products by Top 10 Mechanism of Actions, H2 2015 26
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015 26
Number of Products by Stage and Top 10 Routes of Administration, H2 2015 28
Number of Products by Top 10 Molecule Types, H2 2015 29
Number of Products by Stage and Top 10 Molecule Types, H2 2015

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report